(Q36677966)

English

A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer

scientific article published on 14 December 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 August 2017

A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer (English)

1 reference

Europe PubMed Central

15 August 2017

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

12

object named as

George Wilding

1 reference

Europe PubMed Central

15 August 2017

author name string

Dustin A Deming

1

1 reference

Europe PubMed Central

15 August 2017

Ludmila L Cavalcante

2

1 reference

Europe PubMed Central

15 August 2017

Sam J Lubner

3

1 reference

Europe PubMed Central

15 August 2017

Daniel L Mulkerin

4

1 reference

Europe PubMed Central

15 August 2017

Noelle K LoConte

5

1 reference

Europe PubMed Central

15 August 2017

Jens C Eickhoff

6

1 reference

Europe PubMed Central

15 August 2017

Jill M Kolesar

7

1 reference

Europe PubMed Central

15 August 2017

Suzanne Fioravanti

8

1 reference

Europe PubMed Central

15 August 2017

Tim F Greten

9

1 reference

Europe PubMed Central

15 August 2017

Kathryn Compton

10

1 reference

Europe PubMed Central

15 August 2017

Austin G Doyle

11

1 reference

Europe PubMed Central

15 August 2017

Austin Duffy

13

1 reference

Europe PubMed Central

15 August 2017

Glenn Liu

14

1 reference

Europe PubMed Central

15 August 2017

publication date

14 December 2015

1 reference

Europe PubMed Central

15 August 2017

Investigational New Drugs

1 reference

Europe PubMed Central

15 August 2017

34

1 reference

Europe PubMed Central

15 August 2017

2

1 reference

Europe PubMed Central

15 August 2017

168-175

1 reference

Europe PubMed Central

15 August 2017

https://scigraph.springernature.com/pub.10.1007/s10637-015-0314-7

0 references

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4788533

30 September 2017

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4788533

30 September 2017

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4788533

30 September 2017

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4788533

30 September 2017

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4788533

30 September 2017

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4788533

30 September 2017

EGFR antagonists in cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4788533

30 September 2017

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4788533

30 September 2017

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4788533

30 September 2017

Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4788533

30 September 2017

The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4788533

5 September 2018

Stability of cetuximab and panitumumab in glass vials and polyvinyl chloride bags.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4788533

5 September 2018

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4788533

5 September 2018

Identifiers

10.1007/S10637-015-0314-7

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36677966&oldid=1590518927"